Apomorphine does not influence olfactory thresholds in Parkinson's disease. 1998

J Roth, and T Radil, and E Růzicka, and R Jech, and J Tichý
Clinic of Neurology, Charles University, Prague, Czech Republic.

In order to verify the presumed dopaminergic basis of olfactory dysfunction in Parkinson's disease (PD), we studied olfactory functions in 12 PD patients (mean age 60.1 yrs, mean duration of PD 9.0 yrs, mean Hoehn and Yahr score 2.8) before and after apomorphine (APO) administration. Amylacetate (banana smell) in 12 sequential dilutions (in 50% steps) was used for the examination of olfactory thresholds. The testing showed no significant differences in any olfactory parameters before and after APO. Furthermore, when analysing the subgroup of 7 hyposmic PD patients, we also found no significant differences before and after APO. We therefore believe that olfactory dysfunction in PD is not dependent on dopamine deficiency.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009068 Movement The act, process, or result of passing from one place or position to another. It differs from LOCOMOTION in that locomotion is restricted to the passing of the whole body from one place to another, while movement encompasses both locomotion but also a change of the position of the whole body or any of its parts. Movement may be used with reference to humans, vertebrate and invertebrate animals, and microorganisms. Differentiate also from MOTOR ACTIVITY, movement associated with behavior. Movements
D009833 Olfactory Pathways Set of nerve fibers conducting impulses from olfactory receptors to the cerebral cortex. It includes the OLFACTORY NERVE; OLFACTORY BULB; OLFACTORY TRACT; OLFACTORY TUBERCLE; ANTERIOR PERFORATED SUBSTANCE; and OLFACTORY CORTEX. Olfactory Pathway,Pathway, Olfactory,Pathways, Olfactory
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001058 Apomorphine A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use. Apokinon,Apomorphin-Teclapharm,Apomorphine Chloride,Apomorphine Hydrochloride,Apomorphine Hydrochloride Anhydrous,Apomorphine Hydrochloride, Anhydrous,Apomorphine Hydrochloride, Hemihydrate,Britaject,Apomorphin Teclapharm
D012684 Sensory Thresholds The minimum amount of stimulus energy necessary to elicit a sensory response. Sensory Threshold,Threshold, Sensory,Thresholds, Sensory
D018491 Dopamine Agonists Drugs that bind to and activate dopamine receptors. Dopamine Receptor Agonists,Dopaminergic Agonists,Agonists, Dopamine Receptor,Agonists, Dopaminergic,Dopamine Agonist,Dopamine Receptor Agonist,Dopaminergic Agonist,Receptor Agonists, Dopamine,Agonist, Dopamine,Agonist, Dopamine Receptor,Agonist, Dopaminergic,Agonists, Dopamine,Receptor Agonist, Dopamine

Related Publications

J Roth, and T Radil, and E Růzicka, and R Jech, and J Tichý
February 2014, Chemical senses,
J Roth, and T Radil, and E Růzicka, and R Jech, and J Tichý
December 2004, Movement disorders : official journal of the Movement Disorder Society,
J Roth, and T Radil, and E Růzicka, and R Jech, and J Tichý
January 1951, Transactions of the American Neurological Association,
J Roth, and T Radil, and E Růzicka, and R Jech, and J Tichý
November 2020, Journal of neurology,
J Roth, and T Radil, and E Růzicka, and R Jech, and J Tichý
May 1994, Postgraduate medical journal,
J Roth, and T Radil, and E Růzicka, and R Jech, and J Tichý
April 1989, Journal of neurology, neurosurgery, and psychiatry,
J Roth, and T Radil, and E Růzicka, and R Jech, and J Tichý
April 1988, Lancet (London, England),
J Roth, and T Radil, and E Růzicka, and R Jech, and J Tichý
February 1998, BMJ (Clinical research ed.),
J Roth, and T Radil, and E Růzicka, and R Jech, and J Tichý
January 1991, Lancet (London, England),
J Roth, and T Radil, and E Růzicka, and R Jech, and J Tichý
May 1991, Neurology,
Copied contents to your clipboard!